AIM ImmunoTech Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 15, 2022 08:05 ET | AIM ImmunoTech Inc.
– On track to commence Phase 2 study for lead program evaluating Ampligen® (rintatolimod) for the treatment of pancreatic cancer in Q3 2022 – Well-positioned to achieve multiple near-term...
NOVARTIS logo.jpg
Novartis provides update on Phase III CANOPY-A study evaluating canakinumab as adjuvant treatment in non-small cell lung cancer
August 15, 2022 01:15 ET | Novartis Pharma AG
 Phase III CANOPY-A trial did not meet primary endpoint of disease-free survival in patients with stages II-IIIA and IIIB completely resected non-small cell lung cancer1Findings will be presented at...
Onconova Logo BLUE.jpg
Onconova Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
August 11, 2022 16:05 ET | Onconova Therapeutics, Inc.
NEWTOWN, Pa., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
MNPR Triangle 2.JPG
Monopar Therapeutics Reports Second Quarter 2022 Financial Results and Recent Program Developments
August 11, 2022 08:05 ET | Monopar Therapeutics Inc.
WILMETTE, Ill., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary...
RevolutionLogo.png
Revolution Medicines Reports Second Quarter 2022 Financial Results and Update on Corporate Progress
August 09, 2022 16:02 ET | Revolution Medicines, Inc.
First two RAS(ON) Inhibitor drug candidates advance into clinical development Successful equity financing supports development of portfolio of targeted drug candidates for RAS-addicted cancers ...
BioNTech and Genmab Expand Global Strategic Collaboration to Develop and Commercialize Novel Immunotherapy Candidates
August 05, 2022 06:45 ET | BioNTech SE
Collaboration expands to include development of monospecific antibody candidates to address malignant solid tumors Expanded collaboration leverages Genmab’s proprietary HexaBody® technology platform...
BioNTech und Genmab erweitern globale strategische Kollaboration zur Entwicklung und Vermarktung neuartiger Immuntherapiekandidaten
August 05, 2022 06:45 ET | BioNTech SE
Ausweitung der Kollaboration zur Entwicklung monospezifischer Antikörperkandidaten gegen bösartige solide TumoreKollaboration nutzt Genmabs firmeneigene HexaBody®-Technologieplattform, um neuartige...
CURE Media Group Opens Nominations for Multiple Myeloma Heroes® Award Program
August 04, 2022 15:54 ET | CURE Media Group
The Recognition Will Honor Individuals Who Have Made a Significant Difference in the Lives of Those Affected by Multiple Myeloma CRANBURY, N.J., Aug. 04, 2022 (GLOBE NEWSWIRE) -- CURE Media...
Across the U.S., Cancer Survivors, Caregivers, and their Loved Ones will Climb for a Cure
August 03, 2022 10:46 ET | Fight Colorectal Cancer
Springfield, Mo., Aug. 03, 2022 (GLOBE NEWSWIRE) -- On August 6 and 7, Fight Colorectal Cancer (Fight CRC), a national nonprofit organization, and advocates from across the country will be hosting...
Kinnate_LogoColor@10x.png
Kinnate Biopharma Inc. to Participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference
August 02, 2022 16:05 ET | Kinnate Biopharma
SAN FRANCISCO and SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that its chief...